2,763 Natera, Inc. $NTRA Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. decreased its holdings in Natera, Inc. (NASDAQ:NTRA) by 11.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 20,402 shares of the medical research company’s stock after selling 2,763 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Natera were worth $8,432,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NTRA. BlackRock Inc. bought a new stake in shares of Natera during the 2nd quarter worth $2,962,770,000. Arrowstreet Capital Limited Partnership grew its position in Natera by 1.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after acquiring an additional 11,793 shares during the last quarter. Maverick Capital Ltd. raised its stake in Natera by 24.1% during the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after acquiring an additional 227,605 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Natera by 10.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after acquiring an additional 80,440 shares in the last quarter. Finally, Bank of America Corp DE bought a new position in shares of Natera in the second quarter worth about $199,960,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on NTRA. Guggenheim raised their price target on shares of Natera from $360.00 to $475.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research report on Thursday, October 15th. Roth Capital began coverage on shares of Natera in a research note on Thursday, October 22nd. They issued a “buy” rating and a $475.00 price objective for the company. Stephens raised their target price on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, Robert W. Baird cut their target price on shares of Natera from $458.00 to $403.00 and set an “outperform” rating on the stock in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $394.31.

Natera Trading Down 2.6%

Natera stock opened at $311.98 on Wednesday. The stock has a 50-day moving average price of $379.93 and a two-hundred day moving average price of $270.42. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41. The company has a market capitalization of $45.24 billion, a PE ratio of -273.67 and a beta of 1.55.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. The firm had revenue of $793.98 million for the quarter, compared to the consensus estimate of $707.54 million. During the same quarter last year, the firm posted ($0.64) earnings per share. The business’s revenue for the quarter was up 34.1% on a year-over-year basis. As a group, analysts predict that Natera, Inc. will post -1.20 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, insider Solomon Moshkevich sold 3,419 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $409.77, for a total value of $1,401,003.63. Following the completion of the transaction, the insider directly owned 101,323 shares in the company, valued at approximately $41,519,125.71. This represents a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 302 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $400.01, for a total transaction of $120,803.02. Following the transaction, the insider directly owned 195,276 shares of the company’s stock, valued at $78,112,352.76. The trade was a 0.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 47,056 shares of company stock valued at $17,760,989 in the last quarter. 5.05% of the stock is currently owned by corporate insiders.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% to about $794 million, beating estimates, and Natera raised its 2026 sales outlook as test volumes—particularly oncology testing—accelerated. NTRA Q3 Loss Wider Than Expected, Revenues Beat, ’26 Sales View Up
• Positive Sentiment: Management highlighted a long-term goal of $6 billion in revenue by 2029, supported by Signatera growth, broader reimbursement and continued investment. Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook
• Positive Sentiment: Natera is collaborating with Incyte on a Phase 2 colorectal cancer trial, which could support its oncology testing business, though the commercial impact will depend on trial results and adoption. Natera Launching Collaboration With Incyte for Phase 2 Trial to Treat Colorectal Cancer
• Neutral Sentiment: A report listed short interest at zero shares as of November 10, a figure that does not indicate meaningful short positioning; the report’s description of a significant increase appears inconsistent with that number.
• Negative Sentiment: Despite the revenue beat, Natera’s quarterly loss of $0.42 per share was wider than the $0.28 loss analysts expected, highlighting ongoing profitability concerns. NTRA Q3 Loss Wider Than Expected, Revenues Beat, ’26 Sales View Up
• Negative Sentiment: Analysts cut price targets, including Robert W. Baird’s reduction to $403 from $458, while maintaining an Outperform rating. JPMorgan also reportedly lowered its target, adding a cautious note despite the improved outlook. Robert W. Baird Stock Recommendations Natera Stock Gets Price Target Cut from JPMorgan Chase & Co.

Natera Company Profile

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.